Production Cell Engineering to Reduce Endogenous Protein Burden
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high cost of producing recombinant therapeutic proteins in mammalian cell expression systems contributes to increasing global health costs, necessitating the development of methods to enhance yield and quality.
Innovation Solution
Reducing the level of non-essential, redundant, and/or secreted endogenous proteins in production cells through genetic modifications such as deletions, substitutions, or insertions, or using siRNA to target regulatory nucleic acid sequences, thereby increasing the yield and quality of recombinant polypeptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If endogenous proteins are reduced through genetic modification, then product yield increases, but cell complexity increases
Solution Approach 1:
The patent extracts and removes non-essential endogenous proteins from the host cell through genetic modification techniques such as CRISPR-Cas9, RNA interference, and homologous recombination. This extraction of unnecessary cellular components directly increases product yield by redirecting cellular resources toward recombinant protein production while managing cell complexity through targeted removal rather than addition of components.
2Quantity of substance
If non-essential endogenous proteins are removed, then resource allocation for product production improves, but manufacturing process complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-modifying host cells to remove non-essential endogenous proteins before initiating recombinant protein production. This advance preparation optimizes resource allocation from the outset, ensuring that cellular resources are immediately directed toward product synthesis. The manufacturing process complexity is managed through standardized genetic modification protocols and automated cell line development platforms.
3Manufacturing precision
If endogenous protein levels are reduced, then product purity increases, but production time increases
Solution Approach 1:
The patent replaces mechanical/purification-based approaches with genetic-based solutions by engineering host cells to constitutively express lower levels of endogenous proteins. This substitution eliminates the need for lengthy purification steps to remove endogenous contaminants, thereby achieving high product purity without extending production time. The genetic modification creates a self-regulating system that maintains optimal protein levels throughout the production process.
Data Source
AI summary
The present disclosure features methods, cells or cell lines, and compositions for increasing the amount of products, e.g., proteins, produced by a cell or cell line by reducing the level of a non-essential endogenous protein.